ArticleBMJ case reports2021

Tetrahydrocannabinol and cannabidiol as an oromucosal spray in a 1:1 ratio: a therapeutic option for patients with central post-stroke pain syndrome?

Ulrich MoserPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.